Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Argus Health
Citi
McKesson
Merck
AstraZeneca
Cipla
Deloitte
Moodys

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RANITIDINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Ranitidine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00000964 The Effect of Stomach Acid on Foscarnet Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 To see if ranitidine, by reducing stomach acidity, can enhance the effectiveness of foscarnet, by making foscarnet more available to the body. Foscarnet is an antiviral compound. Laboratory studies have shown it to be active against HIV. However, only 12 - 22 percent of an oral foscarnet dose is absorbed by the body. Ranitidine suppresses gastric acid output, increasing gastric pH. Thus by increasing gastric pH (decreasing stomach acidity), less foscarnet is expected to be decomposed or broken down in the stomach. Thus, more foscarnet should be absorbed into the body.
NCT00002106 A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3 Completed Glaxo Wellcome Phase 2 To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.
NCT00037570 Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 2 This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients. Patients will receive either intravenous pantoprazole (one of two regimens) or ranitidine (the comparator) within 2 hours of successful hemostasis and administration will continue for 72 hours after hemostasis.
NCT00146549 Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer Completed Brigham and Women's Hospital Phase 3 The purpose of this study is to compare two different combinations of chemotherapy with trastuzumab as initial treatment for HER2 positive advanced breast cancer. Half of the patients will receive trastuzumab in combination with a taxane form of chemotherapy (either paclitaxel or docetaxel), while the other group will receive trastuzumab in combination with vinorelbine.
NCT00146549 Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer Completed GlaxoSmithKline Phase 3 The purpose of this study is to compare two different combinations of chemotherapy with trastuzumab as initial treatment for HER2 positive advanced breast cancer. Half of the patients will receive trastuzumab in combination with a taxane form of chemotherapy (either paclitaxel or docetaxel), while the other group will receive trastuzumab in combination with vinorelbine.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ranitidine Hydrochloride

Condition Name

Condition Name for Ranitidine Hydrochloride
Intervention Trials
Healthy 6
Dyspepsia 4
Postoperative Pain 3
Gastroesophageal Reflux Disease (GERD) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ranitidine Hydrochloride
Intervention Trials
Ulcer 6
Pain, Postoperative 5
Gastroesophageal Reflux 5
Dyspepsia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ranitidine Hydrochloride

Trials by Country

Trials by Country for Ranitidine Hydrochloride
Location Trials
United States 73
China 18
Korea, Republic of 12
Egypt 9
Taiwan 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ranitidine Hydrochloride
Location Trials
California 11
Texas 8
Florida 5
Illinois 4
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ranitidine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ranitidine Hydrochloride
Clinical Trial Phase Trials
Phase 4 26
Phase 3 14
Phase 2 23
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ranitidine Hydrochloride
Clinical Trial Phase Trials
Completed 51
Recruiting 15
Not yet recruiting 8
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ranitidine Hydrochloride

Sponsor Name

Sponsor Name for Ranitidine Hydrochloride
Sponsor Trials
AstraZeneca 6
Mansoura University 5
Boehringer Ingelheim 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ranitidine Hydrochloride
Sponsor Trials
Other 89
Industry 38
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Moodys
Julphar
Fish and Richardson
Queensland Health
Federal Trade Commission
Farmers Insurance
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.